Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways

Trends in Immunology

Volumn 38, Issue 3, 2017, Pages 194-205

  Zevini, Alessandra ^a   Olagnier, David ^b   Hiscott, John ^a  

^a Pasteur Institute   (Italy)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP GMP SYNTHASE; CYCLIC GMP; LIGAND; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; STIMULATOR OF INTERFERON GENES PROTEIN; UNCLASSIFIED DRUG; BACTERIAL DNA; DDX58 PROTEIN, HUMAN; MB21D1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; NUCLEOTIDYLTRANSFERASE; PATTERN RECOGNITION RECEPTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; VISA PROTEIN, HUMAN;

CANCER IMMUNOTHERAPY; CYTOPLASM; CYTOSOL; HUMAN; INNATE IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VIRUS IMMUNITY; ANIMAL; BACTERIAL INFECTION; IMMUNOLOGY; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BACTERIAL INFECTIONS; DEAD BOX PROTEIN 58; DNA, BACTERIAL; HUMANS; IMMUNITY, INNATE; MEMBRANE PROTEINS; NUCLEOTIDYLTRANSFERASES; RECEPTOR CROSS-TALK; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION;

EID: 85009274995     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.12.004     Document Type: Review

References (91)

1. 1 Chow, J., et al. PRRs are watching you: localization of innate sensing and signaling regulators. Virology 479–480 (2015), 104–109.
2. 2 Kawasaki, T., Kawai, T., Toll-like receptor signaling pathways. Front. Immunol., 5, 2014, 461.
3. 3 O'Neill, L.A., et al. The history of Toll-like receptors – redefining innate immunity. Nat. Rev. Immunol. 13 (2013), 453–460.
4. 4 Hoving, J.C., et al. Signalling C-type lectin receptors, microbial recognition and immunity. Cell Microbiol. 16 (2014), 185–194.
5. 5 Schlee, M., Hartmann, G., Discriminating self from non-self in nucleic acid sensing. Nat. Rev. Immunol. 16 (2016), 566–580.
6. 6 Yoneyama, M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5 (2004), 730–737.
7. 7 Belgnaoui, S.M., et al. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr. Opin. Immunol. 23 (2011), 564–572.
8. 8 Yoneyama, M., Viral RNA detection by RIG-I-like receptors. Curr. Opin. Immunol. 32 (2015), 48–53.
9. 9 Gack, M.U., Mechanisms of RIG-I-like receptor activation and manipulation by viral pathogens. J. Virol. 88 (2014), 5213–5216.
10. 10 Peisley, A., Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I. Nature 509 (2014), 110–114.
11. 11 Hou, F., MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146 (2011), 448–461.
12. 12 Jacobs, J.L., Coyne, C.B., Mechanisms of MAVS regulation at the mitochondrial membrane. J. Mol. Biol. 425 (2013), 5009–5019.
13. 13 Pattabhi, S., Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway. J. Virol. 90 (2016), 2372–2387.
14. 14 Beljanski, V., Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J. Virol. 89 (2015), 10612–10624.
15. 15 Chiang, C., Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J. Virol. 89 (2015), 8011–8025.
16. 16 Paludan, S.R., Bowie, A.G., Immune sensing of DNA. Immunity 38 (2013), 870–880.
17. 17 Unterholzner, L., The interferon response to intracellular DNA: why so many receptors?. Immunobiology 218 (2013), 1312–1321.
18. 18 Sun, L., et al. Cyclic GMP–AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339 (2013), 786–791.
19. 19 Schoggins, J.W., A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472 (2011), 481–485.
20. 20 Zhang, X., The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep. 6 (2014), 421–443.
21. 21 Zhang, X., Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 2013 (2013), 226–235.
22. 22 Ablasser, A., et al. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature 498 (2013), 380–384.
23. 23 Gao, P., et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP–AMP synthase. Cell 153 (2013), 1094–1107.
24. 24 Civril, F., Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498 (2013), 332–337.
25. 25 Sun, W., ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 8653–8658.
26. 26 Zhong, B., The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29 (2008), 538–550.
27. 27 Ishikawa, H., Barber, G.N., STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455 (2008), 674–678.
28. 28 Jin, L., MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol. Cell Biol. 28 (2008), 5014–5026.
29. 29 Marchi, S., et al. The endoplasmic reticulum-mitochondria connection: one touch, multiple functions. Biochim. Biophys. Acta 1837 (2014), 461–469.
30. 30 Yin, Q., Cyclic di-GMP sensing via the innate immune signaling protein STING. Mol. Cell 46 (2012), 735–774.
31. 31 Wang, Q., et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity 41 (2014), 919–933.
32. 32 Mukai, K., et al. Activation of STING requires palmitoylation at the Golgi. Nat. Commun., 7, 2016, 11932.
33. 33 Abe, T., Barber, G.N., Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J. Virol. 88 (2014), 5328–5341.
34. 34 Zhong, B., et al. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity 30 (2009), 397–407.
35. 35 Wang, Y., et al. TRIM30alpha is a negative-feedback regulator of the intracellular DNA and DNA virus-triggered response by targeting STING. PLoS Pathog., 11, 2015, e1005012.
36. 36 Bridgeman, A., Viruses transfer the antiviral second messenger cGAMP between cells. Science 349 (2015), 1228–1232.
37. 37 Gentili, M., Transmission of innate immune signaling by packaging of cGAMP in viral particles. Science 349 (2015), 1232–1236.
38. 38 Ablasser, A., Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503 (2013), 530–534.
39. 39 Chen, Q., et al. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17 (2016), 1142–1149.
40. 40 Brunette, R.L., et al. Extensive evolutionary and functional diversity among mammalian AIM2-like receptors. J. Exp. Med. 209 (2012), 1969–1983.
41. 41 Chiu, Y.H., et al. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138 (2009), 576–591.
42. 42 van Montfoort, N., Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors. Cytokine Growth Factor Rev. 25 (2014), 657–668.
43. 43 Doitsh, G., Greene, W.C., Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe. 19 (2016), 280–291.
44. 44 Jakobsen, M.R., et al. Innate immune sensing of HIV-1 infection. Curr. Opin. HIV. AIDS 10 (2015), 96–102.
45. 45 Sze, A., et al. Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe 14 (2013), 422–434.
46. 46 Gao, D., et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341 (2013), 903–906.
47. 47 Mankan, A.K., Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. EMBO J. 33 (2014), 2937–2946.
48. 48 Herzner, A.M., et al. Sequence-specific activation of the DNA sensor cGAS by Y-form DNA structures as found in primary HIV-1 cDNA. Nat. Immunol. 16 (2015), 1025–1033.
49. 49 Ishikawa, H., et al. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461 (2009), 788–792.
50. 50 Chen, L.L., et al. Molecular basis for an attenuated cytoplasmic dsRNA response in human embryonic stem cells. Cell Cycle 9 (2010), 3552–3564.
51. 51 Nazmi, A., et al. STING mediates neuronal innate immune response following Japanese encephalitis virus infection. Sci. Rep., 2, 2012, 347.
52. 52 Nitta, S., et al. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology 57 (2013), 46–58.
53. 53 Holm, C.K., et al. Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses. Nat. Commun., 7, 2016, 10680.
54. 54 Yu, C.Y., et al. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog., 8, 2012, e1002780.
55. 55 Aguirre, S., et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog., 8, 2012, e1002934.
56. 56 Suzuki, T., et al. Cell type-specific subcellular localization of phospho-TBK1 in response to cytoplasmic viral DNA. PLoS One, 8, 2013, e83639.
57. 57 Sali, T.M., et al. Characterization of a novel human-specific STING agonist that elicits antiviral activity against emerging alphaviruses. PLoS Pathog., 11, 2015, e1005324.
58. 58 Hartlova, A., et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42 (2015), 332–343.
59. 59 Liu, Y., et al. RIG-I-Mediated STING upregulation restricts herpes simplex virus 1 infection. J. Virol. 90 (2016), 9406–9419.
60. 60 Huang, Z., et al. Cloning and functional characterization of rat stimulator of interferon genes (STING) regulated by miR-24. Dev. Comp. Immunol. 37 (2012), 414–420.
61. 61 Sui, H., et al. siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway. Nucleic Acids Res. 42 (2014), 583–598.
62. 62 Schoggins, J.W., et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505 (2014), 691–695.
63. 63 Thompson, M.R., et al. Interferon gamma-inducible protein (IFI) 16 transcriptionally regulates type i interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses. J. Biol. Chem. 289 (2014), 23568–23581.
64. 64 Ahn, J., Barber, G.N., Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Curr. Opin. Immunol. 31 (2014), 121–126.
65. 65 Klarquist, J., et al. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J. Immunol. 193 (2014), 6124–6134.
66. 66 Woo, S.R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
67. 67 Deng, L., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41 (2014), 843–852.
68. 68 Takashima, K., et al. STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation. Biochem. Biophys. Res. Commun. 478 (2016), 1764–1771.
69. 69 Gutjahr, A., et al. Triggering intracellular receptors for vaccine adjuvantation. Trends Immunol., 37, 2016, 716.
70. 70 Chandra, D., et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2 (2014), 901–910.
71. 71 Wang, Z., Celis, E., STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol. Immunother. 64 (2015), 1057–1066.
72. 72 Nakamura, T., et al. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J. Control Release 216 (2015), 149–157.
73. 73 Conlon, J., et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 190 (2013), 5216–5225.
74. 74 Corrales, L., et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11 (2015), 1018–1030.
75. 75 Fu, J., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med., 7, 2015, 283ra52.
76. 76 Chen, Q., et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533 (2016), 493–498.
77. 77 Tang, C.K., et al. The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant. PLoS One, 8, 2013, e60038.
78. 78 Ahn, J., et al. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun., 5, 2014, 5166.
79. 79 Huang, L., et al. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J. Immunol. 191 (2013), 3509–3513.
80. 80 Lemos, H., et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 76 (2016), 2076–2081.
81. 81 Poeck, H., et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14 (2008), 1256–1263.
82. 82 Van, D.N., et al. Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J. 26 (2012), 3188–3198.
83. 83 Besch, R., et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 119 (2009), 2399–2411.
84. 84 Ellermeier, J., et al. Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 73 (2013), 1709–1720.
85. 85 Su, Z.Z., et al. Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression. J. Cell Physiol. 213 (2007), 502–510.
86. 86 Liu, Z., et al. Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. Oncotarget 7 (2016), 25350–25365.
87. 87 Wang, J.H., et al. microRNA-34a-upregulated retinoic acid-inducible gene-I promotes apoptosis and delays cell cycle transition in cervical cancer cells. DNA Cell Biol. 35 (2016), 267–279.
88. 88 Hou, J., et al. Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell 25 (2014), 49–63.
89. 89 Szabo, A., et al. RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1. Cell Signal. 28 (2016), 335–347.
90. 90 Ranoa, D.R., et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 7 (2016), 26496–26515.
91. 91 Hochheiser, K., et al. Cutting edge: the RIG-I ligand 3pRNA potently improves CTL cross-priming and facilitates antiviral vaccination. J. Immunol. 196 (2016), 2439–2443.